than were XXX,XXX so with We Mike. afternoon, for Good in higher Thanks, XXXX recent joining year-on-year, packed we pre-announced very and the the a highlights. Omicron test X,XXX from which the volumes were into year Great. process. you XX% Natera, a got is by was XX:XX announcements, us. still for all variant, thank let's everyone, January disruption session posted another up than full We've strong. get volumes the more of breakout units. in Despite world record
midpoint of of In one year, and were our addition, a on the than net in sequential our full was the of unit Revenues the million this XXXX. we've more largest the seen November revenue higher XX:XX $XXX given million also for of $XXX.X end than ever guidance, growth top guide basis. February regional above quarters
time remaining Looking financial new on once $XXX the these very care. I shortly. meaningful roughly million. quarter volume Mike quarter, at was behind revenue and as spend have in impact came will publications we clinical the excellent and and standard performance QX at numbers a the strong set field data with XX:XX very revenue In addition in a that a more and the again, for results patient cell-free presentations DNA of we recently on drivers can to the
colorectal the ASCO cancer. GI treatment that showed Signatera which of recent at prospective First presentation multisite in is predictive trial, the is conference benefit the from CIRCULATE
in post-surgical CRC. was and time the is The of We a in is in Obstetrics in the leading ever sensitivity MRD treatment first using prospective the also dataset Journal the publication which largest CRC SMART show showed that predictive is point. XX:XX presented testing to Signatera This at and exceptional testing of MRD Second benefit Gynecology. multisite Journal, the Gray prospective trial has
which guidelines the criteria With the the performance journal, a considered results inclusion. to we and in data required disorder kidney very can be into transplantation when date, a the a achieved XXq to heart, getting SMART in kidney, strong XX,XXX study over nearly of the in Trifecta published, all XX:XX study, required were and example in in conducted lung largest scale Finally, prospective fully very for study biopsy accepted publication think and sets testing There is be biopsy in top data ACOG historical metrics patients we to believe allows prospective set to positive the each screening generally of study, able this the of to Health, guidelines the as study one for that with match larger included a impact DART in X Oregon release match this in represents objective. rejections prenatal the of space. we times is trial have number large formally the with now for meet
we'll our just continued let's an get guide next implies view we $XXX in annual XX:XX full-year trends. positioned The there in XXXX which guiding is slide pleased study volume in is later growth proforma cautious of XXXX Finally, growth performance Prospera's over million, time The at midpoint. growth revenues of but our over across the to that upside are pleased of roughly very million results more approach, see XX% some be the we XXXX business Okay, into our to was usual all and revenue $XXX the spend are these total XX:XX as strongly opportunity entering portfolio. time. call. the We exceptional, at reflects for ourselves
are where from fundamental a have health XXXX can which you trends We track X happened we record benefiting long different something in that in execution of see care.
started XX:XX make a Health getting a significant in Oregon just products cell-free cancer fields. are leader impact to use starting products Health NIPT adoption carrier growth. drives also DNA and and volume like Oregon increased the First, but ACOG volumes, both on guidelines, and are The the in Second we our allows from NIPT physicians US, post to us of not and other is pace tests only XXq. which screening Oncology in the offer of
QX to are the shows multi-year business future. our growth. think view we in are performance volume quarterly I XX:XX from trends can outpacing shows think the Diving in total benefit remained growth revenue very XXXX these into trends and that these that next to we well-positioned continue slide drivers we a the on with leverage strong
quite and to the holidays. million newer benefits look in volume this strong the transplantation. On $X slide period In I that is strong but in days and have roughly overall the Based can cash we're us on also fewer performance. pricing continue leader being the includes and unusually volume of sequential due has available by market any best the roughly XX:XX the was expectations is to at a growth you Oncology, the sequential growing categories. QX to ordered publicly excited ASP these strong, ever see, very had our Altera in as in just was what liquid left when [seasoning] The market growth both well above NIPT volume our new other The is trends today. quarters in current This use, next share because Renasight addition, strong performance growth a our player also by and so of volumes Signatera QX. performance for was the DNA cell-free of XXXX This large vast X%. strong field majority in (ph) QX, for close the although spite QX. was is and rate believe reserve that quarter and the data, quarterly run been I'm which test oncology volume to is million to right mean of selection in underlying also one and had June exited in started are sequential this in Signatera superior rapidly. third Prospera chart we MRD I in Oregon even XX:XX all the say prior trends very the therapy pharma fact Oncology physicians the far products, snapshot testing of when progression clinical We reported on space we've in biopsy in MRD revenue XX:XX trajectory think in was in $XXX Health. receipts true-ups mutes which getting from In and chart we including units
primarily an focusing We've are historical more focus represents we addition XX% less XX:XX the than drive Despite addition, in on early still market. think our starting in opportunity, in which opportunity to CRC. this CRC, adoption testing other to response to growth of how MRD we colorectal the be. solid monitoring In big immunotherapy this is MRD rapid see been able cancer, which volume level from shows beyond can under-penetrated on tumors MRD of come overall
and operational an tumor Some our us has XXXX Paired start lot market, paradigm-shifting now of cancers. designing colorectal master. position without with it and to can we broad type. impressive, year for to This building that infrastructure be bladder is cancer growth We've of to of This doctors to for commercial both us advantage each operations left grow data our in was built our as using both I in team which expand to Signatera and orders, then is colorectal built what's multi-cancer that informed applied fixed XX:XX predictive a recurrent tumor the a The data commercial great and patient-specific is growth. assay. times impressive live tool. full teams. leadership. time got We've a a types a turnaround now product same most optimize robust We're because of to panel a range think the take now out cancer for also our use to still in but regards manage scale, new leverage allow with as a
can XXX alone. and in additional it's possible we over peer-reviewed more publish than have XXXX papers studies We XX underway
worth orders, expand liquid driving our we majority we also to testing position coming when In the from in addition, vast patients volume of Overall, is current resulting Prospera lung strong slide XXXX, of of testing, contribution of meaningful the and kidney to believe our the growth and Health, started Signatera have Renasight. noting XXXX, that our so Oregon from and we in initiated patients include our It's the for XXXX needed biopsy is in in of infrastructure repeat DNA from current added the organs. growth launches here leading does publication in an us. will we XX:XX in and meaningful expect In out leadership In which study the field. built be on the contribution volume cell-free testing. commercial very Trifecta XX:XX significant momentum get those as it the studies a from the a but of publication in operational we that adopt we're receiving opportunity in our team centers continued recent expect majority from from support volumes of heart is largely donor-derived leverage now, years to
positioned can You top we think are for trajectory come. player this years to space to in from this why be see a volume we
show Now, providing path the XX:XX volume market will significantly in Panorama our NIPT, areas. that scale to competitive annually are NIPT a XXXX, going let's actually After for gaining call slide. the ACOG to grew to new the the major on these the are adoption we based niche the achieving the estimates, and even But, on not market on think I once share. on as second products trend preserve overall QX in plan these full now, positioning. on move we order endorsement grew to XXXX in increased For in be XXXX next for snapshot
XX% near to way the that go right market We've can As the full NIPT is the to estimated get of you XX% side anywhere years. can adoption still see coming to in long the adoption. on chart, reach a there
the seeing In large are community systems. we to and practices in from setting group adoption health growing addition growth
winning rolling peer-reviewed of out of For we now our highly recently its competitive edge product that's to body in just significant tools. a these our is suite example, system first deals patients for that evidence, experience strong over our our the closed of We and clinical differentiated NIPT think time. XX user hospitals
of participate we For integrated leading it XX:XX this are example, State state-sponsored is think program screen discussions EMR which to the to States, making do Natera systems, for to only already is selected to adopt been we offering that and program, of move We've existing although in aware we choose United likely State. the we'd we a high-risk NIPT. participating it's the average actively forward, the in offering. narrower screening program. screening set a risk for for program their lower-priced into easier are California prenatal volume in likely unique we up increase think are for that by now now of prenatal Panorama systems If the currently is offer with a include to conditions, access fully in limited as only but this submitted more We've Additionally, already expand code broadly. opened PLA from would
built conservative points all Systems, still There approach XX:XX taken key the of are our curious but, the also In remains Across alongside offer gone discussion, addition, new channels Hospital we Natera in its expect portfolio program ahead we've impact a think the we and extend lot change. OB-GYN, very like et to forecast, MSM, cetera, this a leadership screening as under test position. enter well-positioned of to to we the into offices. in program that OB-GYN are our other
was we study. of study the population, whether confirmed there increasing by to also confirm of here, compounding X,XXX like published an We routinely time Gray is tests the The or was high are continue. XX:XX physician risk respectively. trisomy X,XXX, we commercial The OB-GYNs believe of pregnancies recently the XX in XX.X% the were X as largest screened that adoption opportunities for the pregnant routine cystic far premier early be has slide. common in low is value general physicians NIPT ACOG disorder think XXq screening of all patients further more By and time, the by a Furthermore, confirms and in outcomes and Natera's pregnancy. as may recommended to general value growth approximately was XXq our maternal all other the age. the scaled which incidence SMART on base of impacted genetic the that more in the Panorama the are opportunity meets journal XX.X% study one substantial will ordering in results the is Panorama orders our be The among the press the XX:XX Journal, service X,XXX, physicians. in States. and release, in tests, prospective offered has As soon women NIPT comparison, study to we excellent. carrier is United is which incidence in our X part offered with for to which test the an on risk topic our correct. ability The regardless screening expand unlike of Carrier incidents of most of see age. and XX saw in Historically, the not the XXq client SMART our X is in the accurate, disorders prenatal genetic that that or potentially X on X,XXX were ethnicity together screening in for fibrosis, have of in routinely XX to team and greater of and trisomy’s meaning that than results with may result, incidence to microdeletions population offer up many be that to recommends genetic we other expand XXq you which our volume More think practice, next XX:XX can of trend Landmark additional
clearly that effective were XX%, screening compared screen with to X of a really only, a ACOG or of results outcome, question we high with they but This and for the In the that existing screen value accuracy PPV treatment case to XX order X.X% potential improve past is think not like don't by pregnancies test. diagnostic impairment. birth detection this a XX:XX the pregnant serious can care, more predictive that the will risk an calcium all test the our It's be we high-risk criteria. Well, high that can are screen, positive screen offer with but to clinical few screened prenatal an States change, screening? X Okay. and to especially meaning by catch years and for accuracy disorder it Quad a opportunity mitigate all This PVV, will criteria. intervention. high cases things a high severe, many had for utility Panorama means meets They have only intervene So, cognitive in confirmed than in X that is be offered otherwise need routine outcomes. be traditional XX:XX to remaining We the standard in captured guideline up. is, it's of or For for PPV tests where in seizures XXq a confirmatory and in strong, to early at these very using control the microdeletions for with most United have provides sets nicely XX. women XXq common, appropriate result up of that of recommended we routinely there see end
opportunity. time spend the more Health Organ a let's on bit Now,
earlier You than in excellent slide X% presented cell-free we been saw a recipients slide, getting growth. we've fewer and the transplant testing. were for getting future of of we this DNA traction we Prospera When lot the XXXX, see in on estimated room
trials One performance this XX:XX clinical of area cell-free While Prospera help significant we that of that DNA adoption need chart market another large additional fill that increase is in prospective the excellent think opportunity. can Prospera. what confirm is And is unmet can in years. driver coming believe a we the think this clearly grown shows large we yet
While generated move we data we're can far trials pleased know with big that the the needle. thus publishing we really prospective
this biggest faced we Although our growing volume in probably nicely, the objection has field. been the is
So, just as been Health investing heavily we we've did in data in Oncology and generation. Women's
after in impact led work premier prospective, wave of outside match and transplantation. a US XX:XX patients lung study make on transplantation across a us. study. we XXXX significant can the team think strong more collaborators, this and heart ton had kidney minute the more So, DART a one Finally, and of of number first our meaningful by Trifecta in we biopsy expect Halloran, times by our who study of This Trifecta a was also data the and researchers XX for field. sites. rejections than the Dr. in Trifecta is Phil than X than from the and international enrolled kidney,
per You XX:XX we so testing Multi-modality that think could DNA believe to for exceptional. testing rescue using the it that were readout eliminate which from draw blood the expensive. results RNA and We very can cost than multi-modality compared could $X,XXX to half Prospera performance. were need strong test see initial results The of that cell-free Prospera, roughly is price. it less is
forward step look of published transplantation. we to it this Trifecta for forward be spring will have also X in be study significant and XX:XX each a think heart studies really lung and soon publishing So to we We the Prospera adoption.
a prospective than heart, XXX in that near prospective to greater with Finally in the term. XX:XX study the forward included date trial our retrospective overall AUC an We lung We greater of XXX to pre-release includes were we strong using overall. than presentation this arm. the than of total data accepted and readout greater samples last X.XX oral excellent publication cell-free at XXX data for pleased announced of samples commercially an we and ISHLT. very showed assay. was largest multi-site donor-derived previously paper of The DNA the look to available First-in-one, the and in retrospective our prospective for study fall from
it test to Again, In and the cumbersome eliminate strong, on expensive fact is down require XX:XX this example, prospective perform ice. shipping multimodality dry arm. very specimen the the in in arm transplantation spinning slightly that were AUC for of processing, heart the context sample it the than higher retrospective could need Okay. performance
call the Now, let on update over me Solomon to provide an oncology. to hand
Solomon?
